A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01163929
Recruitment Status : Withdrawn (Study closed by Protocol Review Monitoring Committee because of lack of accrual)
First Posted : July 16, 2010
Last Update Posted : October 24, 2012
Information provided by (Responsible Party):
University of Kansas Medical Center ( University of Kansas )

July 14, 2010
July 16, 2010
October 24, 2012
July 2010
March 2012   (Final data collection date for primary outcome measure)
assess complete response rate [ Time Frame: 5 months ]
To assess the pathological complete response rate (pCR) with of 4 cycles of neoadjuvant Herceptin plus Paclitaxel and Everolimus in patients with operable HER-2 positive breast cancer.
Same as current
Complete list of historical versions of study NCT01163929 on Archive Site
assess objective/radiological response rate and tolerability [ Time Frame: 5 months ]
The secondary outcome is to assess the objective/radiological response rate and to assess tolerability of the proposed treatment regimen
Same as current
Not Provided
Not Provided
A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer
A Phase II Neoadjuvant Study of RAD001 (Everolimus) in Combination With Paclitaxel and Trastuzumab For Operable HER2 Positive Breast Cancer
The primary objective of this study is to assess whether a combination of chemotherapy, Trastuzumab and RAD001 will result in no evidence of microscopic disease at the time of surgery in 50% of enrolled patients.

This is an open-label Phase 2 neoadjuvant study for patients with histologically confirmed, HER-2 positive operable breast cancer. All patients will receive 18 weeks of neoadjuvant treatment.

The trial has an initial 2 week "biomarker lead in" phase. During this two week phase patients will either receive Trastuzumab alone or Trastuzumab + Everolimus. This two week lead in phase will be randomized open label. The rest of the 16 weeks of the neoadjuvant trial treatment is non randomized open label.

For the first two weeks of neoadjuvant treatment the eligible subjects will be randomly assigned to either receive or not receive Everolimus. This assignment will be accomplished by a previously prepared schedule (maintained by the investigational pharmacy), such that investigators are unaware of assignment until after the subject has been enrolled on the study and received assignment of Everolimus or not.

Phase 2
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Breast Cancer
Drug: paclitaxel


80mg/m2 IV TRO 3 hours every 28 days for 4 cycles


4mg/kg IV load dose (TRO 90) minutes followed by 2 mg/kg TRO 60 minutes every week for 18 weeks

Everolimus: 10mg PO daily 16-18 weeks

Other Names:
  • Taxol
  • Herception
  • RAD001
Experimental: paclitaxel, trastuzumab and everolimus
Intervention: Drug: paclitaxel
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2012
March 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female ≥ 18 to 65 years of age
  • Histologically proven stage I, II or III adenocarcinoma of breast
  • Candidate for adjuvant chemotherapy and Trastuzumab (Tumor size > 1 cm, T2, T3, T4 and/or clinical N1 or N2)
  • HER-2 positive breast cancer (IHC 3+ or FISH ratio of > 2.0)
  • ECOG Performance status 0-2
  • No prior chemotherapy or HER-2 targeted therapy for breast cancer
  • Not pregnant or breast feeding or adult of reproductive potential using effective birth control methods. If barrier contraceptives are used, these must be continued throughout trial by both sexes. Hormonal contraceptives not acceptable as a sole method of contraception. Women of childbearing potential must have negative urine or serum pregnancy test within 7 days before administration of RAD001
  • Adequate bone marrow function: ANC > 1500/mm3, platelet count > 100,000/mm3, and hemoglobin > 11 g/dL
  • Adequate kidney function: serum creatinine of < 1.5mg/dl and/or creatinine clearance of > 60 mL/min
  • Adequate hepatic function: transaminase < 2 x upper limit of normal and total bilirubin < 1.5 mg/dL.
  • INR ≤2.0 and PTT 1.5 X the upper limit of institution normal range. Oral anticoagulants, eg,warfarin are CYP2C9 substrates and as such, no interaction with RAD001 is expected. Anticoagulation with Coumadin allowed if target INR is ≤2.0 and stable for > 2 weeks. Anticoagulation with LMWH is allowed.
  • Must sign informed consent
  • Pretreatment lab values for CBC and CMP performed within 14 days of registration and other baseline studies within 30 days.
  • Will have baseline mammogram, bone scan, CT chest and abdomen within 60 days of registration.
  • Adequate cardiac function (Cardiac ejection fraction ≥ 50% as measured by echocardiogram or MUGA scan).
  • Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, patient can only be included after initiation of appropriate lipid lowering medication.

Exclusion Criteria:

  • Prior HER-2 targeted therapy for breast cancer
  • Metastatic disease
  • Uncontrolled intercurrent illness including but not limited to, ongoing or active infection requiring parenteral antibiotics or psychiatric illness/social situations that would limit compliance with study requirements.
  • GI tract disease resulting in inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease eg, Crohn's, ulcerative colitis).
  • Current active hepatic or biliary disease (exception of patients with Gilbert's syndrome, asymptomatic gallstones)
  • Renal function as measured by creatinine clearance <30ml/min (ratio to norm <0.1)
  • Pregnant
  • Inflammatory breast cancer
  • Active cardiac disease, defined as:

    • History of uncontrolled or symptomatic angina
    • History of arrhythmias requiring medications, or clinically significant, with exception of asymptomatic atrial fibrillation requiring anticoagulation
    • Myocardial infarction < 6 months from study entry
    • Uncontrolled or symptomatic congestive heart failure
    • Any other cardiac condition, which in opinion of treating physician, would make this protocol unreasonably hazardous for the patient
  • History of another primary cancer, with the exception of:

    • curatively resected nonmelanomatous skin cancer
    • curatively treated cervical carcinoma in-situ
    • other primary solid tumor curatively resected,treated with no known active disease present and no treatment administered for the last 3 years.
  • Life expectancy of < 2 months
  • Receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
  • Should not receive immunization with attenuated live vaccines within 1 week of study entry or during study period
  • Severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air
  • Uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN
  • Active (acute or chronic) or uncontrolled severe infections
  • Known history of HIV seropositivity
  • Active, bleeding diathesis
  • Patients who have received prior treatment with an mTOR inhibitor (Sirolimus, Temsirolimus, Everolimus).
  • Known hypersensitivity to RAD001 (Everolimus) or other rapamycins (Sirolimus, Temsirolimus) or to its excipients
  • Active Hepatitis B or C infection
  • > 65 years of age
Sexes Eligible for Study: Female
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
Not Provided
Not Provided
University of Kansas Medical Center ( University of Kansas )
University of Kansas
Principal Investigator: Priyanka Sharma, MD University of Kansas Medical Center
University of Kansas Medical Center
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP